Bavarian Nordic A/S (OTCMKTS:BVNRY) Reaches New 1-Year High at $19.31

Bavarian Nordic A/S (OTCMKTS:BVNRYGet Rating)’s stock price reached a new 52-week high on Thursday . The stock traded as high as $19.31 and last traded at $19.15, with a volume of 885017 shares changing hands. The stock had previously closed at $18.27.

Analyst Ratings Changes

Separately, Cowen raised Bavarian Nordic A/S from a “market perform” rating to an “outperform” rating in a research note on Wednesday, July 20th.

Bavarian Nordic A/S Stock Down 6.0 %

The firm’s fifty day simple moving average is $12.09 and its 200-day simple moving average is $9.92.

Bavarian Nordic A/S (OTCMKTS:BVNRYGet Rating) last announced its earnings results on Monday, May 9th. The company reported ($0.20) earnings per share (EPS) for the quarter, missing the consensus estimate of ($0.15) by ($0.05). The business had revenue of $48.26 million for the quarter, compared to the consensus estimate of $54.80 million. Bavarian Nordic A/S had a negative net margin of 35.74% and a negative return on equity of 9.17%. As a group, sell-side analysts predict that Bavarian Nordic A/S will post -0.73 EPS for the current fiscal year.

Bavarian Nordic A/S Company Profile

(Get Rating)

Bavarian Nordic A/S develops, manufactures, and commercializes life-saving vaccines. The company offers non-replicating smallpox and monkeypox vaccines under the IMVAMUNE, IMVANEX, and JYNNEOS names; rabies vaccine for human use under the Rabipur/RabAvert name; tick-borne encephalitis vaccine under the Encepur name; and Ebola vaccine under the MVABEA name.

Featured Stories

Receive News & Ratings for Bavarian Nordic A/S Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Bavarian Nordic A/S and related companies with's FREE daily email newsletter.